HELX vs XBI

HELXCFranklin Genomic Advancements ETF

XBIAState Street SPDR S&P Biotech ETF

In short

HELX Most genomics funds hand you an index. Franklin's take is a stock-picker's portfolio of roughly 60 global names tied to gene sequencing, gene therapy and precision medicine, launched in 2020 with a plain mandate: capital appreciation.

XBI Biotech's great leveler. Its index weights roughly 160 US biotechs near-equally, so a clinical-stage minnow carries about as much as a megacap. Live since 2006 and one of the most heavily traded funds in the sector.

Stated mandate

HELX The Fund seeks capital appreciation.

XBI The fund seeks to track, before fees and expenses, the total return performance of the S&P Biotechnology Select Industry Index.

Why people hold it

• HELX A concentrated bet, not a basket: about 60 global holdings across the genomics chain, so individual breakthroughs actually move the fund instead of being diluted by hundreds of names.
• Global by design. The mandate is not fenced to US listings, which matters in a field where sequencing and gene-therapy leaders sit in Europe and Asia too.
• Fee sits right at the middle of the genomics and biotech peer group at 0.50%, so you are not paying a premium over the typical thematic competitor for a discretionary approach.
• Live since 2020, giving it a multi-year record through a brutal stretch for biotech, rather than a launch-window track record.

• XBI Modified equal weighting spreads exposure across roughly 160 biotechs instead of a handful of giants, so small drug developers actually move the fund.ssga.com
• 0.35% a year sits below the typical fee in its biotech peer group, which is unusual for a specialist sleeve this narrow.
• Among the most heavily traded funds in biotech and multi-billion-dollar in size, so getting in and out is rarely the hard part.
• A 2006 launch from State Street's SPDR line, meaning it has traded through several biotech booms and busts rather than one hot cycle. Pays quarterly.

Worth knowing

• HELX It is a small, thinly traded fund. Use limit orders, expect wider spreads than the big index names, and know that small ETFs carry more closure risk than entrenched ones.
• The low-cost, high-liquidity lane in this category belongs to index products like IBBQ (0.19%) and IBB (0.44%). HELX's case rests on the manager's picks, not on price or trading ease.
• Genomics is a growth-style, high-volatility corner of health care. Clinical trial results and rate moves can swing a 60-stock portfolio hard in both directions.

• XBI Equal weighting leans hard on smaller, clinical-stage names where a single trial readout moves a stock, so swings run deeper than cap-weighted rivals like IBB.ssga.comnasdaqomx.com
• Not the cheapest ticket on the shelf: Invesco's IBBQ charges 0.19% against XBI's 0.35%.
• One US industry only, drawn from the biotechnology segment of the S&P Total Market Index, so it can drift a long way from the broad market either direction.ssga.com

Full HELX profile⁠

Full XBI profile⁠